NO20044312L - Fluorerte 4-azasteroidderivater som androgenreseptorrnodulatorer - Google Patents
Fluorerte 4-azasteroidderivater som androgenreseptorrnodulatorerInfo
- Publication number
- NO20044312L NO20044312L NO20044312A NO20044312A NO20044312L NO 20044312 L NO20044312 L NO 20044312L NO 20044312 A NO20044312 A NO 20044312A NO 20044312 A NO20044312 A NO 20044312A NO 20044312 L NO20044312 L NO 20044312L
- Authority
- NO
- Norway
- Prior art keywords
- fluorinated
- androgen receptor
- receptor modulators
- azasteroid derivatives
- azasteroid
- Prior art date
Links
- 150000000520 4-azasteroids Chemical class 0.000 title 1
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36382202P | 2002-03-13 | 2002-03-13 | |
PCT/US2003/008277 WO2003077919A1 (en) | 2002-03-13 | 2003-03-07 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044312L true NO20044312L (no) | 2004-10-12 |
Family
ID=28041817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044312A NO20044312L (no) | 2002-03-13 | 2004-10-12 | Fluorerte 4-azasteroidderivater som androgenreseptorrnodulatorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US7186838B2 (no) |
EP (1) | EP1485095A4 (no) |
JP (2) | JP4516316B2 (no) |
KR (1) | KR100938136B1 (no) |
CN (1) | CN1652786A (no) |
AU (1) | AU2003218235B2 (no) |
BR (1) | BR0308355A (no) |
CA (1) | CA2478186C (no) |
EC (1) | ECSP045287A (no) |
HR (1) | HRP20040822A2 (no) |
IL (2) | IL163825A0 (no) |
IS (1) | IS7425A (no) |
MA (1) | MA27112A1 (no) |
MX (1) | MXPA04008800A (no) |
NO (1) | NO20044312L (no) |
NZ (1) | NZ534946A (no) |
PL (1) | PL372920A1 (no) |
RU (1) | RU2320670C2 (no) |
UA (1) | UA78029C2 (no) |
WO (1) | WO2003077919A1 (no) |
ZA (1) | ZA200406843B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
PL372920A1 (en) * | 2002-03-13 | 2005-08-08 | Merck & Co,Inc. | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
ATE376444T1 (de) * | 2002-05-10 | 2007-11-15 | Hoffmann La Roche | Ibandronsäure zur behandlung und vorbeugung von osteoporose |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US20070088042A1 (en) * | 2004-09-09 | 2007-04-19 | Meissner Robert S | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
CN1849120A (zh) * | 2003-09-10 | 2006-10-18 | 默克公司 | 作为雄激素受体调节剂的17-杂环-4-氮杂甾类衍生物 |
AU2004281708B2 (en) * | 2003-10-14 | 2011-02-17 | University Of Tennessee Research Foundation | Treating bone-related disorders with selective androgen receptor modulators |
US7312229B2 (en) * | 2003-10-31 | 2007-12-25 | Merck & Co., Inc. | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
CN1930181A (zh) | 2004-01-07 | 2007-03-14 | 恩多研究公司 | 螺旋12定向的甾族药品 |
US20080125403A1 (en) * | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
CA2564564A1 (en) * | 2004-04-28 | 2005-11-10 | Merck & Co., Inc. | Fluorinated 4-azasteroids as androgen receptor modulators |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
EP1784187A4 (en) * | 2004-08-25 | 2010-08-18 | Merck Sharp & Dohme | MODULATORS OF THE ANDROGEN RECEPTOR |
EP2371367A1 (en) * | 2005-03-25 | 2011-10-05 | Merck Sharp & Dohme (I.A.) Corp. | Method of treating men with testosterone supplement and 5alpha reductase inhibitor |
US7301026B2 (en) * | 2005-05-05 | 2007-11-27 | Merck & Co., Inc | Process for making fluorinated 4-azasteroid derivatives |
TW200730505A (en) * | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US8183286B2 (en) | 2006-11-16 | 2012-05-22 | Gemmus Pharma Inc. | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
US8304539B2 (en) * | 2008-02-07 | 2012-11-06 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
KR102122941B1 (ko) | 2012-07-13 | 2020-06-15 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
US9566310B2 (en) * | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
US9707210B2 (en) | 2013-03-15 | 2017-07-18 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
KR101586345B1 (ko) * | 2014-08-06 | 2016-01-18 | 한국생명공학연구원 | 에스트라디올 벤조에이트(Estradiol benzoate) 또는 이의 약학적으로 허용 가능한 염을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
HRP20221196T1 (hr) | 2017-10-05 | 2022-12-09 | Fulcrum Therapeutics, Inc. | Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd |
CN114805462A (zh) | 2018-02-11 | 2022-07-29 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
WO2021023213A1 (zh) | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
CN112851745B (zh) * | 2021-01-25 | 2021-11-16 | 广西民族大学 | 氮杂甾体吡啶类化合物及其合成与应用 |
WO2022271951A1 (en) | 2021-06-23 | 2022-12-29 | University Of Iowa Research Foundation | Sustained release formulations comprising a selective androgen receptor modulator |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187278A (en) | 1990-08-27 | 1993-02-16 | Merck & Co., Inc. | Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-aza-5α-androstan-3-one steroids |
GB9216284D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives |
TW408127B (en) * | 1993-09-17 | 2000-10-11 | Glaxo Inc | Androstenones |
JPH11512434A (ja) * | 1995-09-15 | 1999-10-26 | メルク エンド カンパニー インコーポレーテッド | アンドロゲン過剰状態治療用の4−アザステロイド |
WO1998025623A1 (en) * | 1996-12-09 | 1998-06-18 | Merck & Co., Inc. | Methods and compositions for preventing and treating bone loss |
PL372920A1 (en) * | 2002-03-13 | 2005-08-08 | Merck & Co,Inc. | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
-
2003
- 2003-03-07 PL PL03372920A patent/PL372920A1/xx not_active Application Discontinuation
- 2003-03-07 KR KR1020047014281A patent/KR100938136B1/ko not_active IP Right Cessation
- 2003-03-07 WO PCT/US2003/008277 patent/WO2003077919A1/en active Application Filing
- 2003-03-07 MX MXPA04008800A patent/MXPA04008800A/es active IP Right Grant
- 2003-03-07 CN CNA038104857A patent/CN1652786A/zh active Pending
- 2003-03-07 JP JP2003575972A patent/JP4516316B2/ja not_active Expired - Fee Related
- 2003-03-07 IL IL16382503A patent/IL163825A0/xx unknown
- 2003-03-07 US US10/507,239 patent/US7186838B2/en not_active Expired - Fee Related
- 2003-03-07 CA CA2478186A patent/CA2478186C/en not_active Expired - Fee Related
- 2003-03-07 BR BR0308355-1A patent/BR0308355A/pt not_active IP Right Cessation
- 2003-03-07 EP EP03714228A patent/EP1485095A4/en not_active Withdrawn
- 2003-03-07 AU AU2003218235A patent/AU2003218235B2/en not_active Ceased
- 2003-03-07 RU RU2004130452/04A patent/RU2320670C2/ru not_active IP Right Cessation
- 2003-03-07 NZ NZ534946A patent/NZ534946A/en not_active IP Right Cessation
- 2003-07-03 UA UA20041008266A patent/UA78029C2/uk unknown
-
2004
- 2004-08-26 IS IS7425A patent/IS7425A/is unknown
- 2004-08-27 ZA ZA200406843A patent/ZA200406843B/en unknown
- 2004-08-31 IL IL163825A patent/IL163825A/en not_active IP Right Cessation
- 2004-09-10 HR HR20040822A patent/HRP20040822A2/hr not_active Application Discontinuation
- 2004-09-10 EC EC2004005287A patent/ECSP045287A/es unknown
- 2004-10-07 MA MA27893A patent/MA27112A1/fr unknown
- 2004-10-12 NO NO20044312A patent/NO20044312L/no unknown
-
2010
- 2010-03-12 JP JP2010055367A patent/JP5268975B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HRP20040822A2 (en) | 2005-06-30 |
US20050165039A1 (en) | 2005-07-28 |
JP5268975B2 (ja) | 2013-08-21 |
PL372920A1 (en) | 2005-08-08 |
IL163825A (en) | 2010-12-30 |
EP1485095A4 (en) | 2009-11-18 |
ZA200406843B (en) | 2007-06-27 |
EP1485095A1 (en) | 2004-12-15 |
CN1652786A (zh) | 2005-08-10 |
JP2010168391A (ja) | 2010-08-05 |
IS7425A (is) | 2004-08-26 |
ECSP045287A (es) | 2004-10-26 |
BR0308355A (pt) | 2005-01-25 |
IL163825A0 (en) | 2005-12-18 |
NZ534946A (en) | 2007-05-31 |
JP4516316B2 (ja) | 2010-08-04 |
WO2003077919A1 (en) | 2003-09-25 |
JP2005526082A (ja) | 2005-09-02 |
MA27112A1 (fr) | 2004-12-20 |
UA78029C2 (en) | 2007-02-15 |
KR20040097167A (ko) | 2004-11-17 |
CA2478186A1 (en) | 2003-09-25 |
AU2003218235A1 (en) | 2003-09-29 |
CA2478186C (en) | 2011-08-23 |
RU2320670C2 (ru) | 2008-03-27 |
KR100938136B1 (ko) | 2010-01-22 |
RU2004130452A (ru) | 2005-04-10 |
MXPA04008800A (es) | 2004-11-26 |
US7186838B2 (en) | 2007-03-06 |
AU2003218235B2 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044312L (no) | Fluorerte 4-azasteroidderivater som androgenreseptorrnodulatorer | |
EP1581217A4 (en) | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR | |
EP1501512A4 (en) | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | |
DK1663996T3 (da) | (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister | |
DK1487806T3 (da) | 4-anilin-quinazolinderivater som antiproliferative midler | |
NO20044654L (no) | Piperidinoylpiperidiner som 5-HTIF-agonister | |
DK1735286T3 (da) | Tetrahydroindazoler som cannabinoidmodulatorer | |
DK1656345T3 (da) | Cykliske derivater som modulatorer af chemokinreceptoraktivitet | |
NO20054951D0 (no) | Prostaglandinanaloger som EP4-reseptorantagonister | |
DK1505974T3 (da) | Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer | |
DK1492789T3 (da) | Tropanderivater som CCR5-modulatorer | |
NO20042955L (no) | Substituerte fenylaftalener som estrogene midler | |
DK1521733T3 (da) | Modulatorer af glucocorticoid receptoren | |
DK1501826T3 (da) | Substituerede indoler som alpha-1-agonister | |
DK1501809T3 (da) | Trizolderivater som tachykininreceptorantagonister | |
DK1503984T3 (da) | 8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk | |
DK1809624T3 (da) | Pyrimidinsulfonamidderivater som kemokinreceptor-modulatorer | |
EP1670483A4 (en) | 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules | |
DK1567493T3 (da) | Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer | |
NO20043794L (no) | Benzensulfonamidderivater som antipsykotiske midler | |
DK1578727T3 (da) | Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer | |
NO20035183D0 (no) | 5-substituerte-2-arylpyridiner som CRF1 modulatorer | |
NO20034130L (no) | Benzimidazolderivater som modulerer kjemokinreseptor | |
EP1656142A4 (en) | 6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS MODULATORS ANDROGEN RECEPTOR COMPOUNDS | |
EP1663228A4 (en) | USE OF 17-HETEROCYCLIC-4-AZASTEROIDIAN DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR |